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Review Current implications of cyclophilins in human 
cancers
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Abstract
Cyclophilins (Cyps), the intracellular receptor for immu-
nosuppressant cyclosporine A (CsA), play important cel-
lular roles through activities of peptidyl-prolyl cis-trans
isomerase (PPIase) and chaperones. Cyps are structurally
conserved and found in both prokaryotic and eukaryotic
organisms, including humans which contain 16 Cyp iso-
forms. Although human Cyps were identified about 25
years ago, their physiological and pathological roles have
only been the focus of attention recently because of their
possible involvement in diseases and ailments such as
HIV infection, hepatitis B and C viral infection, athero-
sclerosis, ER stress-related diseases and neurodegenera-
tive diseases, etc. There are reports for upregulated Cyps
in many human cancers and there are also strong correla-
tions found between Cyps overexpression and malignant
transformation. This review discusses the important and
diverse roles of Cyps overexpression in human cancers.
Understanding biological functions of Cyps will eventu-
ally lead to improved strategies for cancer treatment and
prevention.
Introduction
Cyclophilins (Cyps) were initially identified as biological
receptors for the immunosuppressive drug cyclosporine
A (CsA) approximately 25 years ago. Later, they were
shown to have peptidyl-prolyl cis-trans isomerase
(PPIase) enzymatic activity which catalyzes cis-trans
isomerization of peptide bonds preceding proline [1-6].
Cyps also possess chaperone activities. These two func-
tions allow Cyps to be involved in proper folding of pro-
teins in combination with other proteins. Although CsA
is an effective inhibitor of Cyps, immunosuppressive
activity of CsA is not the result of inhibition of the Cyps'
activities. Rather, the Cyp-CsA complex accidentally
inhibits calcineurin activity and thereby suppresses T-cell
proliferation by interfering with downstream signal trans-
duction [7].
Cyps are highly conserved from E. coli to humans
throughout evolution. A total of 16 Cyp isoforms have
been found in humans [8], but 7 major human Cyp iso-
forms, namely hCypA, hCypB, hCypC, hCypD, hCypE,
hCyp40, and hCypNK [9], have been well characterized.
They play diverse roles by localizing through unique
domains for particular cellular compartments including
the cytosol, endoplasmic reticulum (ER), mitochondria
and nucleus. The clinical importance of Cyps has been
implicated in diverse pathological conditions including
HIV [10], hepatitis B and C viral infection, atherosclerosis
[11,12], ER stress-related diseases such as diabetes, and
neurodegenerative diseases. Cyps are also involved in
normal cellular functions of muscle differentiation,
detoxification of reactive oxygen species (ROS) [13], and
immune response [14]. Their novel and unfamiliar nucle-
ase activity similar to apoptotic endonucleases suggests a
potential role in apoptotic DNA degradation. Overall
roles of Cyps may encompass far more than already
defined functions such as protein folding.
CypA overexpression in diverse types of cancer has
been recently reported by many research groups. Subse-
q u e n t l y ,  o v e r e x p r e s s i o n  o f  o t h e r  C y p s  h a s  a l s o  b e e n
repeatedly observed in various cancers. Although Cyps
expression levels and patterns in many cancer types have
been considerably well documented, the precise roles of
Cyps in cancer are hardly defined. Here, we will discuss
the implications of Cyps in cancer biology and particu-
larly give emphasis on CypA that has been studied most
extensively in diverse human cancers. Better understand-
ing of Cyps' function in cancers may divulge their poten-
tial applications in cancer prevention, diagnosis, and
treatment.
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Regulation of Cyclophilin A gene expression in 
human cancers
After the initial finding of upregulation of CypA in hepa-
tocellular carcinoma [15,16], CypA has been reported to
be overexpressed in small cell lung cancer [17-20], pan-
creatic cancer [21-25], breast cancer [26,27], colorectal
cancer [28-30], squamous cell carcinoma [31,32], mela-
noma [33], and glioblastoma multiforme [34]. In addition
to CypA's automatic malregulation in diverse cancers,
CypA can be influenced in its expression by chemothera-
peutic agents. Independent research groups demon-
strated that treatment with chemotherapeutic agents, 5-
aza-2-deoxycytidine (DAC), celecoxib, and 5-fluorouracil
(5-FU), lowers CypA expression [[21,29] and [30]]. On
the contrary, our group found that cisplatin causes CypA
overexpression and induces resistance to diverse chemo-
therapeutic agents including cisplatin (unpublished data).
Upregulation of CypA in cancer is not so unusual; yet the
exact mechanisms of transcriptional alteration of CypA
in cancer are still elusive.
Initially, CypA gene together with those of glyceralde-
hyde 3-phosphate dehydrogenase, rRNA and beta-actin
was considered one of the constitutively expressed house-
keeping genes which do not respond to external stimuli.
Considering the chaperone activity of CypA protein, it is
not surprising to find up-regulation of CypA gene in
response to stresses that can cause protein damage or
denaturation [35]. Since molecular regulatory mecha-
nisms of CypA expression are poorly understood, it needs
to be further studied whether the CypA up-regulaion in
cancer is controlled by the same regulatory mechanisms
of stress induction.
If up-regulation of CypA in cancers is linked to p53 and
HIF-1α, most well-characterized cancer-related tran-
scriptional regulatory factors, has been sought by several
groups. Choi et al. demonstrated that HIF-1α can upreg-
ulate CypA by HIF-1α binding to hypoxia response ele-
ments (HRE) in the CypA promoter region under hypoxic
conditions [36]. Similarly, Gu et al. first showed that
CypA is up-regulated during p53-induced apoptosis
using quantitative proteomic profiling [37,38]. They also
proposed that transcription of CypA might be induced by
activated p53. While no direct evidence has been
reported that p53 is activated or stabilized by CypA, it is
interesting to note that PIN 1, another type of PPIases,
stabilizes p53 through affinity binding of PIN 1 to the
p53's proline rich domain (PRD) [39]. Our group recently
discovered binding activity of CypA to p53 which leads to
stabilization of p53 (unpublished data).
Clinical implications of the overexpressed 
Cyclophilin A in cancers
Upregulation of CypA in many cancer types dictates an
advantage of CypA overexpression toward cancer devel-
opment. While the exact roles of CypA in cancer cells are
yet to be defined, understanding the precise function of
CypA during tumor development will be critical to assess
its potential as a target for therapeutic intervention.
P o s i t i v e  g r o w t h  e f f e c t  b y  e x c e s s i v e  C y p A  o n  c a n c e r
cells was first reported by Howard et al. They showed
that overexpression of CypA in small cell lung cancer
stimulates cancer cell growth, and knockdown of CypA
slows cancer cell growth, independent of its effects on
angiogenesis [17,18]. Other roles of CypA have also been
proposed. Qi et al. suggested that CypA is upregulated
during malignant tansformation of esophageal squamous
cells [32]. CypA abundance is more than 5 fold, compared
to non-malignant immortalized control cell lines [40].
There also exist reports that CypA may regulate metasta-
sis [32,33].
During development of solid tumors, ROS are continu-
ously generated in tumor's central hypoxic region. Hong
et al. suggested that CypA has antioxidant effects through
its PPIase activity [13]. It is consistent with the finding
that CypA overexpression promotes cancer cell prolifera-
tion and blocks apoptosis induced by hypoxia [36]. Choi
et al. showed that overexpression of CypA in cancer cells
renders resistance to hypoxia- and cisplatin-induced cell
death in a p53 independent manner [36].
There are several reports suggesting that inhibition of
PPIase activity of CypA may generate potential chemo-
therapeutic effects. Yurchenko et al. has reported that cell
surface expression of CD147, tumor cell-derived collage-
nase stimulatory factor, is regulated by CypA [41,42].
Overexpressed CypA interacts with the proline-contain-
ing peptide in CD147's transmembrane domain and stim-
ulates human pancreatic cancer cell proliferation [43].
Zheng et al. also demonstrated in breast cancer cells that
prolactin needs to bind CypA for cancer progression and
tumor metastasis [44]. Han et al. showed that CsA and
sanglifehrin A (SfA), two CypA inhibitors, increase che-
motherapeutic effect of cisplatin in glioblastoma multi-
forme [34]. Overexpression and known functional roles
of CypA in various cancer types are summarized in Table
1.
Other cyclophilins and cancers
Other Cyps including CypB, CypC, CypD and Cyp40
might also play important roles in carcinogenesis. Kim et
al. reported that CypB protects cells against ER stress-
induced cell death at least partly through blocking the
Ca2+ leakage from ER to cytosol [45]. Overexpression of
CypB is associated with tumor progression through regu-
lation of hormone receptor expression and gene products
involved in cell proliferation and motility [46]. Interest-
ingly, CypB possesses two antigenic epitopes (CypB (82-
92) and CypB (91-99)) recognized by HLA-A24-
restricted and tumor-specific cytotoxic T lymphocytesTable 1: Cyclophilin A in human cancers
Cancer type Functions and implications of CypA in cancers Contributers
Lung cancer The first identification of CypA overexpression in lung cancer Campa et al., Cancer Res. (2003)
Potential role of CypA in early neoplastic transformation and 
as a biomarker
Howard et al., Lung Cancer (2004)
Regulation of cancer growth, angiogenesisa and apoptosis 
through CypA knockdown and overexpression
Howard et al., Cancer Res. (2005)
Role of exogenous CypA in increased H446 cell growth 
through ERK1/2 pathway activation
Yang et al., BBRC (2007)
Pancreatic cancer Identification of CypA as a decreased factor by 5-aza-2-
deoxycytidine
Cecconi et al., Eletrophoresis (2003)
Involvement of increased CypA in pancreatic carcinogenesis Shen et al., Cancer Res. (2004)
Effect on the gene expression of several key molecules 
including NRPs, VEGF, and VEGFRs
Li et al., Am J Surg (2005)
Stimulation of cancer cell proliferation by increased CypA 
through CD 147 signaling
Li et al., Cancer Res (2006)
Association of increased CypA with tumor invasion, 
metastasis, and resistance to therapy
Mikuriya et al., Int J Oncol (2007)
Hepatocellular 
carcinoma
Regulation of cancer cell proliferation and increase of 
hepatocarcinoma formation by interaction of increased 
CypA with calcineurin
Corton et al., Cancer Let (1998)
Identification as a useful HCC marker in tumor tissues Lim et al., BBRC (2002)
Breast cancer Assessment of CypA down-regulation through proteomics in 
melphalan-resistant and -susceptible MCF-7 cell lines
Hathout et al., J proteomic Res (2002)
Role of CypA in cancer cell progression and regulation of 
JAK2
Zheng et al., Cancer Res (2008)
Colorectal Cancer Identification of association of CypA with tumor 
development and tumor progression through protein 
profiling
Melle et al., Int J Mol Med (2005)
Role of CypA in COX-2-independent chemopreventive effect 
by celecoxib
Lou et al., Cancer Epidemiol (2006)
Upregualtion of CypA among5-fluorouracil (5-FU) response 
proteins for CRC chemotherapy
Wong et al., Oncol Rep (2008)
Squamous cell carcinoma Involvement in oncogenesis in SCC Chen et al., Proteomics (2004)
Possible role as a malignant transformation-related protein 
in ESCC
Qi et al., J Cell Biochem (2008)
Melanoma High level expression in primary and metastatic melanoma Al-Ghoul et al., J Proteome Res (2008)
Prostate cancer Preventing hypoxia- and cisplatin-induced apoptosis Choi et al., Cancer res (2007)
Glioblastoma multiforme Increasing expression of CypA in human glioblastoma 
multiforme
Han et al., Oncol Rep (2010)
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that are suggested to be used for vaccines against cancers
[47].
CypC is another Cyp family member that is primarily
located in ER, but its role remains to be determined.
CypC can form a complex with the COOH-terminal frag-
ment of osteopontin. This complex binds to CD147 to
activate Akt1/2 and MMP-2 in 4T07 murine breast can-
cer cells. This CyC- osteopontin complex regulates in
vitro migration and invasion properties of 4T1 and 4T07
breast cancer cells [48].
CypD is an important component of the mitochondrial
permeability transition pore, another components of
which are the voltage-dependent outer membrane anion
channel, adenine nucleotide translocator [49,50], and
hexokinase. PPIase activity of CypD may be necessary for
binding of CypD to the MPTP complex [51]. Although
function of CypD in mitochondria is controversial, over-
expression of CypD attenuates sensitivity of HEK 293 and
rat glioma C6 cells to apoptotic stimuli, with protective
effects of CypD requiring PPIase activity [52]. Consis-
tently, several reports have shown that CypD is overex-
pressed and has an anti-apoptotic effect in various
tumors via a Bcl 2 collaborator and an inhibitor of cyto-
chrome c release from mitochondria [53]. This protective
effect is independent of the MPTP [53].
Cyp40 mRNA has also been reported to increase in
many breast cancer cell lines including MCF-7 [54].
Additionally, Cyp40 mRNA also increases in response to
high temperature stress in MCF-7 cells [55]. Up-regula-
tion of Cyp40 is reported to be correlated with oxidative
stress in MCF-7 cells and prostate cancer cell lines.
Genetic analysis of breast cancers shows 30% allelic loss
of Cyp40 from patients heterozygous for Cyp40 [56].
Overexpression and potential roles for other Cyps in vari-
ous cancer types are summarized in Table 2.
Summary
Cyps regulate protein folding through PPIase enzymatic
and chaperone activities in specific locales of the cells to
ensure correct conformation and to counterbalance con-
formational variations under diverse stress conditions. In
addition to PPIase and chaperone activities, each isoform
of Cyps has other specific intracellular and extracellular
roles. Although roles of Cyps have recently been explored
in more details, many physiological and pathological
aspects of Cyps' biology still remain unclear.
CypA among the Cyps was first reported to be upregu-
lated in tumors, including small cell lung cancer, pancre-
atic cancer, breast cancer, colorectal cancer, squamous
cell carcinoma, glioblastoma multiforme, and melanoma.
This wide spectrum of cancers harboring excess CypA
denotes an important role of CypA in tumor develop-
ment. The possible roles of CypA in cancers might
involve increased cell proliferation, blockage of apoptosis,
malignant transformation, angiogenesis, metastasis, and
resistance to chemotherapeutic agents. Transcriptional
upregulation of CypA mediated by p53 and HIF-1α dur-
ing tumor development would magnify the cancer-prone
effect of CypA.
S o m e  g r o u p s  h a v e  p r o p o s e d  C y p A  a s  a  c a n c e r  b i o -
marker for certain cancer subtypes because expression
levels nicely correlate with tumor progression. Although
less informed at now, other Cyps are also known to be
overexpressed and proposed to be involved in various
cancers.
CsA and SfA induce apoptosis in various cancer cells
via inhibition of PPIase activity of Cyps, and have been
tested for clinical applications in diverse cancer types
[34]. However, CsA and Sfa can hardly be applied to can-
cer patients because of immunosuppressive effects. The
detailed understanding on the molecular mechanisms by
Table 2: Other cyclophilins in human cancers
Cancer type Isoforms Implications in cancers Contributers
Breast cancer CypB A transcription inducer Fang et al., Am J Pathol. (2009).
Breast cancer Cyp40 Having important functional implications for 
ER alpha and other steroid receptors in breast 
cancer
Eliseev etal., J Biol Chem. (2009)
Increasing in response to high temperature 
stress
Machida etal., J Biol Chem. (2006)
Breast cancer CypC Binding to osteopontin via CD147 and increase 
in migration and invasion
Mi Z et al., Cancer Res. (2007)
Tumors of the breast, ovary, 
and uterus
CypD Inhibition of PT-pore Marzo et al., Cancer Res. (2007)
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which Cyps affect cancer development will aid the devel-
opment of new chemotherapeutic agents. Specific inhibi-
t o r s  o f  t h e  P P I a s e  a c t i v i t y  o f  C y p s  d e v o i d  o f  i m m u n e
suppressive effects will be promising for the treatment of
cancers currently resistant to available chemotherapeu-
tics.
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